GA-FINEOS
14.7.2020 15:17:03 CEST | Business Wire | Press release
FINEOS Corporation (ASX:FCL ), the leading core platform for life, accident and health insurance globally, today announces the appointment of Allison Morgan as Senior Sales Executive to the FINEOS North American team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005639/en/
Allison brings nearly 25 years of proven experience as an accomplished absence and disability sales leader and consultant with powerful relationship building, negotiation, communication and presentation skills. She has a proven track record and demonstrated ability to obtain, grow and retain a customer base to support organizational objectives.
In her new role at FINEOS, Allison will be responsible for developing new business clients for FINEOS Claims , FINEOS Absence and FINEOS AdminSuite . Alison’s expertise in absence management is especially important as Integrated Disability and Absence management (IDAM ) becomes a major product offering for insurance carriers serving the Employee Benefits space. She will work closely with brokers, consultants, and complementary product vendors within the Employee Benefits market.
FINEOS AdminSuite is a modern integrated core processing system that consists of absence, claims, payments, billing, policy, and provider administration – all of which are configurable to operate independently or optimally as a full core suite as part of the SaaS delivered FINEOS Platform , powered by AWS.
Prior to joining FINEOS, Allison worked for eight years at Reed Group, a Guardian company, where she was responsible for new business development of absence management software and outsourcing opportunities, focusing on the design of short and long term disability and absence programs for companies with 5,000 employees and above. Previously, she held senior positions in large insurance companies and brokers including MetLife and Aon Hewitt.
“We are delighted to welcome Allison to the FINEOS team and look forward to working closely with her to continue to help insurance carriers in North America realize the benefits of partnering with FINEOS,” said Michael Kelly , CEO, FINEOS. “In addition to having to transform their business to a fully digital model that delivers excellent customer experience, insurers need to provide risk-based products integrated with comprehensive service offerings that include non-traditional products and services, like IDAM. Our 100% commitment to the Employee Benefits market requires experienced people with a strong understanding of the market today and where it is going in the future. Allison brings that next level of focus on IDAM within the Employee Benefits market for FINEOS. We couldn’t be more pleased to have her on board.”
“I am thrilled to join FINEOS, who is known throughout the insurance industry as the leading provider of core technology solutions. As insurers evaluate their current technology, they are recognizing a critical need to effectively and efficiently meet the growing needs of their customers, both employees and employers, who continue to demand a best-in-class product, service and claims experience enabled by modern technology,” said Allison Morgan, senior sales executive for North America. “Additionally, as entitlement laws continue to pass, insurers need state-of-the-art technology solutions to maintain compliance with various federal, state and local laws. FINEOS brings together all of those considerations to create efficient and robust technology solutions enabling the insurer or Third-Party Administrator to focus on better serving their customers and partnering with FINEOS to achieve their growth objectives.”
About FINEOS Corporation
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides clients full end to end core insurance administration and includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.
For more information, visit www.FINEOS.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005639/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Science21.9.2026 13:02:00 CEST | Press release
BioEridan, a Serbian biotechnology company backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a documentary charting its journey from an early scientific project in Belgrade to an emerging biotechnology venture focused on longevity research BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921345879/en/ BioEridan Documentary Premiere BioEridan: Science Beneath the Surface premiered in Belgrade on September 15 before being screened the following day at a UK-Serbia Health, Digital Transformation & Innovation roundtable held at Christ’s College, University of Cambridge, as part of Cambridge Tech Week 2026. The roundtable brought together prominent representatives fr
LabVantage Named a Visionary Leader in Life Sciences and Industrial LIMS by Frost & Sullivan21.9.2026 10:30:00 CEST | Press release
— Dual recognition in 2026 Frost Radar™ reports marks a fourth consecutive year of Frost Radar leadership — — Frost & Sullivan cited LabVantage CORTEX™ (for life sciences) and LIMS deployments spanning food and beverage, oil and gas, forensics, and government laboratories (for other industrial applications) — LabVantage Solutions, Inc., a leading global provider of laboratory informatics solutions and services, has been named a Visionary Leader in two 2026 Frost Radar™ reports by Frost & Sullivan: Frost Radar™: Life Sciences Laboratory Information Management Systems, 2026 and Frost Radar™: Laboratory Information Management Systems in Industrial Applications, 2026. Announced at LabVantage’s Customer Training and Education Conference (CTEC) Europe 2026 in Paris, the dual recognition marks LabVantage’s fourth consecutive year of Frost Radar leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921487430/en/ The Frost Ra
Bending Spoons opens office in Warsaw as Polish applications reach 50,000 in 202621.9.2026 09:15:00 CEST | Press release
Bending Spoons has opened an office in Warsaw, adding to its Milan headquarters and locations in London and Madrid. The technology company, whose portfolio includes Eventbrite and WeTransfer, has seen a sharp rise in applications from Poland and will use the new base to recruit locally for roles across key projects. “We’ve received around 50,000 applications from Poland so far this year, more than twice as many as the whole of 2025. What stands out isn’t just the volume. Many Polish candidates are among the strongest we see in our selection process, and the student talent has been particularly impressive. More than half of our recent hires from Poland were still studying when they applied,” says Andrea Maiorana, Talent data lead. Located in Śródmieście, Warsaw’s city center, the office is within walking distance of the Presidential Palace and the University of Warsaw. Bending Spoons encourages all new hires to spend their first few months in Milan, with travel and accommodation costs f
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
